The ELGN-GI insulin formulation developed by Israel’s Elgan can save the lives of preterm babies with immature stomachs that cause feeding intolerance. It will avoid the adverse effects of intravenous nutrition, which often leads to infection and liver problems. A Phase 3 trial is being planned.
https://www.jpost.com/health-and-wellness/pregnancy-and-birth/article-699123